• Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers

In the Media

Press Release
In the Media
Events
Syngene expects outsourcing boost from West
17th May, 2023
View
CDMOs will play a vital role in bringing CGT and mRNA technologies to market
3rd May, 2023
View
Can partnerships with CRDMOs boost biosimilar manufacturing
1st Apr, 2023
View
Indian CDMOs now scout for capital-intensive projects and invest in new technologies for global orders
22nd Mar, 2023
View
Syngene's client Panbela announces issuance of new patent in Japan
21st Mar, 2023
View
BW-healthcareworld_Logo
Biologics manufacturing: An opportunity to partner with CRDMOs to bring speed, mitigate risks
20th Feb, 2023
View
Pharmabiz.com_Logo
Indian prowess collaborations propel CRAMS market
16th Feb, 2023
View
BPI-Logo
SARS-CoV-2 variants: A case for expanding mRNA vaccine production globally
9th Feb, 2023
View
Pharmabiz.com-Logo
Biopharma companies of West approach big Indian CROs & CDMOs for multi-dimensional solutions
26th Dec, 2022
View
CFO-Logo
How Syngene International’s CFO is balancing current risks with future viability
22nd Dec, 2022
View
Load More

Sign-up for our newsletter

© 2023. Syngene International Limited

Twitter Linkedin-in Youtube Facebook-f

Quick Links

Business

Get In Touch

Other Links

Twitter Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

Close
Close

To view or email, Please share your details view

To download, Please share your details